Signaturefd LLC Acquires 279 Shares of Cencora, Inc. (NYSE:COR)

Signaturefd LLC lifted its holdings in Cencora, Inc. (NYSE:COR) by 8.4% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 3,614 shares of the company’s stock after acquiring an additional 279 shares during the quarter. Signaturefd LLC’s holdings in Cencora were worth $812,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Hickory Asset Management Inc. bought a new stake in shares of Cencora in the 4th quarter worth approximately $572,000. Sylvest Advisors LLC bought a new stake in shares of Cencora in the 4th quarter worth approximately $1,105,000. Insight Wealth Strategies LLC lifted its holdings in shares of Cencora by 124.6% in the 4th quarter. Insight Wealth Strategies LLC now owns 20,249 shares of the company’s stock worth $4,549,000 after acquiring an additional 11,232 shares during the last quarter. Cerity Partners LLC lifted its holdings in shares of Cencora by 10.1% in the 3rd quarter. Cerity Partners LLC now owns 39,457 shares of the company’s stock worth $8,881,000 after acquiring an additional 3,610 shares during the last quarter. Finally, Vontobel Holding Ltd. increased its stake in shares of Cencora by 46.9% in the fourth quarter. Vontobel Holding Ltd. now owns 6,245 shares of the company’s stock worth $1,403,000 after buying an additional 1,995 shares during the period. 97.52% of the stock is currently owned by institutional investors.

Insider Activity

In other news, CEO Robert P. Mauch sold 4,970 shares of the company’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $255.00, for a total transaction of $1,267,350.00. Following the completion of the sale, the chief executive officer now owns 51,070 shares of the company’s stock, valued at $13,022,850. This represents a 8.87 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Silvana Battaglia sold 5,000 shares of the company’s stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $242.24, for a total transaction of $1,211,200.00. Following the sale, the executive vice president now directly owns 15,374 shares of the company’s stock, valued at $3,724,197.76. The trade was a 24.54 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 13,648 shares of company stock valued at $3,382,462 in the last quarter. 10.80% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on COR. Mizuho began coverage on shares of Cencora in a research note on Wednesday, December 4th. They issued an “outperform” rating and a $280.00 target price on the stock. JPMorgan Chase & Co. lifted their target price on shares of Cencora from $289.00 to $301.00 and gave the stock an “overweight” rating in a research note on Friday, January 24th. Wells Fargo & Company lifted their target price on shares of Cencora from $251.00 to $274.00 and gave the stock an “equal weight” rating in a research note on Friday, March 14th. Evercore ISI lifted their target price on shares of Cencora from $270.00 to $280.00 and gave the stock an “outperform” rating in a research note on Thursday, February 6th. Finally, StockNews.com raised shares of Cencora from a “hold” rating to a “buy” rating in a research note on Wednesday, March 12th. Two analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat, Cencora has an average rating of “Moderate Buy” and an average price target of $280.20.

Cencora Price Performance

COR opened at $266.10 on Thursday. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.54 and a current ratio of 0.92. The stock has a market capitalization of $51.60 billion, a P/E ratio of 37.85, a P/E/G ratio of 1.31 and a beta of 0.51. The company’s 50-day simple moving average is $249.41 and its two-hundred day simple moving average is $239.67. Cencora, Inc. has a 52-week low of $214.77 and a 52-week high of $270.94.

Cencora (NYSE:COR) last posted its earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. As a group, analysts predict that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, March 3rd. Shareholders of record on Friday, February 14th were paid a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a yield of 0.83%. The ex-dividend date of this dividend was Friday, February 14th. Cencora’s dividend payout ratio is currently 31.29%.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.